PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program
PDS Biotechnology Corporation (NASDAQ: PDSB ) shares have fallen by about 67% on Tuesday as the company announced a strategic refocus on its PDS0301 program for metastatic colorectal cancer. PDS0301 Metastatic Colorectal Cancer Focus PDS Biotechnology is prioritizing its PDS0301 program, which targets metastatic colore